Pushing accountable care organizations (ACOs) to take on risk faster will likely result in ACOs that aren’t ready just dropping out of the program and could impact participation in value-based care, said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
Pushing accountable care organizations (ACOs) to take on risk faster will likely result in ACOs that aren’t ready just dropping out of the program and could impact participation in value-based care, said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
Transcript
How do you think CMS pushing ACOs to take on more risk faster with the proposed Pathways to Success will impact participation?
We have some significant concerns about this approach. So, at the end of the day, this is a voluntary program. And if you’re option is take on risk that you’re not ready to assume or drop out of the program, I think we’re going to see ACOs drop out of the program.
And that’s very concerning for us. We’re very supportive of preparing ACOs to take on risk and encouraging ACOs to do so. Where we have concerns is the way in which it’s being done, the time frame in which it’s being done, and more of a stick approach rather than a carrot approach, where we’re making these 2-sided models so much more attractive that people feel that they want to be a part of them.
I think it’s really important to note that the experience ACOs gain in a 1-sided model is what allows them to go through their initial learning curve to prepare to take on risk, and then to, hopefully, show even greater results over time. So, if we’re discouraging new ACOs from joining the program and getting on that learning curve, I think we’re discouraging them from getting on the continuum of value-based care, which is moving generally in the direction of risk.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More